Ovid Therapeutics (NASDAQ:OVID) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Ovid Therapeutics (NASDAQ:OVID) issued its quarterly earnings data on Wednesday. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16, FiscalAI reports. The firm had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.06 million. Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 32.70%.

Here are the key takeaways from Ovid Therapeutics’ conference call:

• Regulatory clearance for the oral KCC2 activator OV4071 (Australia) plus a $60M PIPE and a 30‑day Series A warrant window that could add >$53M — management says this combination gives a pro forma cash runway well into 2029.
• The 7 mg dose of OV329 showed no treatment‑related serious adverse events, no ophthalmic safety signals, and linear PK in healthy volunteers, which management says materially de‑risks the program and supports two doses for Phase II.
• Ovid is expanding OV329 into pediatric/rare indications, initiating signal‑finding and safety studies in infantile spasms and tuberous sclerosis complex (TSC) with plans for weight‑based pediatric formulations and potential efficient combined pivotal pathways.
• Multiple near‑term clinical catalysts are planned — a randomized Phase II FOS trial starting Q2 2026, an open‑label photosensitivity study later in 2026, a Phase I for OV4071 and a ketamine challenge this year — with several readouts expected through 2027.

Ovid Therapeutics Stock Performance

Shares of Ovid Therapeutics stock opened at $2.30 on Friday. The business has a 50-day simple moving average of $1.69 and a 200-day simple moving average of $1.56. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24. Ovid Therapeutics has a one year low of $0.24 and a one year high of $2.50. The company has a market cap of $163.78 million, a PE ratio of -7.42 and a beta of 0.25.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OVID. Goldman Sachs Group Inc. increased its position in shares of Ovid Therapeutics by 497.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 170,457 shares of the company’s stock valued at $278,000 after purchasing an additional 141,940 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of Ovid Therapeutics during the 3rd quarter worth $264,000. Graham Capital Management L.P. acquired a new position in shares of Ovid Therapeutics during the fourth quarter worth $208,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Ovid Therapeutics during the fourth quarter worth $204,000. Finally, Rosalind Advisors Inc. purchased a new position in Ovid Therapeutics in the second quarter valued at $165,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics News Roundup

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: 7 mg OV329 Phase 1 cohort showed favorable safety/tolerability and builds on prior biomarker evidence of cortical inhibition, supporting a planned Phase 2 in treatment‑resistant focal onset seizures (expected Q2 2026). This clinical readout is the main driver behind the stock rally. Read More.
• Positive Sentiment: OV4071 (oral KCC2 activator) received HREC/TGA acknowledgement to enter Phase 1 in Australia, adding a first‑in‑class program to the pipeline and catalyzing nearer‑term clinical milestones (ketamine challenge, proof‑of‑concept). Read More.
• Positive Sentiment: Ovid priced a $60M PIPE financing (led by Point72 and other institutional investors) to fund OV329 expansion into tuberous sclerosis complex (TSC) and infantile spasms and to extend runway into late‑2028. The financing both supplies cash and signals institutional support. Read More.
• Neutral Sentiment: Q4 results beat consensus: GAAP EPS of $0.06 vs. est. (‑$0.10) and revenue ahead of expectations; however, the quarter’s net income was driven largely by a one‑time fair‑value gain on an equity investment. Investors should treat the beat as mixed until recurring revenue or sustained operating profitability appears. Read More.
• Neutral Sentiment: Company laid out a dense near‑term milestone cadence (Phase 2 start in Q2 2026, open‑label photo‑paroxysmal study, ketamine challenge for OV4071, KCC2 R&D day Apr 14). These events could create multiple re‑rating opportunities but also binary risk around each readout. Read More.
• Negative Sentiment: Dilution risk — the PIPE sells shares at $2.01 and includes pre‑funded warrants; separate Series A warrants may be exercisable following OV4071 clearance (potential additional ~$53.9M). Existing shareholders will face near‑term dilution if these instruments are exercised. Read More.
• Negative Sentiment: Underlying fundamentals remain mixed: FY‑2025 net loss of $17.4M, limited recurring revenue, and material operating expenses. The Q4 profit was non‑recurring, so ongoing cash management and execution on trials remain key to valuation. Read More.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on OVID shares. Lifesci Capital initiated coverage on Ovid Therapeutics in a research report on Monday, December 22nd. They issued an “outperform” rating and a $4.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a research note on Monday, December 22nd. Roth Mkm began coverage on Ovid Therapeutics in a report on Thursday, December 11th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Wall Street Zen lowered Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ovid Therapeutics has an average rating of “Buy” and a consensus target price of $4.00.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.